Background: Breast cancer is an extremely complex disease, characterized by a progressive multistep process caused by interactions of both genetic and non-genetic factors. A combination of BRCA1 and BRCA2 gene mutations appears responsible for about 20%-30% of the cases with breast cancer familial history. The prevalence of BRCA1/2 pathogenic mutations largely varies within different populations; in particular, the rate of mutations in Italian breast and/or ovarian cancer families is rather controversial and ranges from 8% to 37%.
introduction
During the last decades several epidemiologic reports have clearly established the role of family history as an important risk factor for both breast and ovarian cancer. In this context, inherited gene mutations are thought to be involved in about 5%-10% of breast and/or ovarian cancer cases. Today, BRCA1 (OMIM #113705) and BRCA2 (OMIM # 600185) are undoubtedly the most important genes for breast and/or ovarian cancer cases, clustering in families with a genetically determined predisposition. Pathogenic mutations in these genes that induce loss of protein function are responsible for about 15%-40% of the breast cancer cases with familial aggregation and for the majority of hereditary ovarian cancer families [1, 2] . BRCA1 and BRCA2 genes are believed to play a key role in maintaining genome integrity and are involved in several aspects of the DNA damage cell response [3, 4] . Women carrying pathogenic mutations on these genes have an increased lifetime risk of developing breast and/or ovarian cancer. The penetrance for BRCA1/2 mutations estimated by the age 70 years broadly ranges from 14% to 87% for breast cancer and 10% to 68% for ovarian cancer. In fact, although initial data from the Breast Cancer Linkage Consortium Study indicated a probability of 85% of developing breast cancer in woman with BRCA genes mutations [5] , more recent studies suggest that the penetrance of BRCA1/2 mutations might be lower in non-high-risk families [6] . Particularly, in the Italian population, the probability of developing a breast or ovarian cancer at age 70 years was estimated to be 39% or 43%, respectively for BRCA1 mutation carrier and 44% and 15% for BRCA2 mutation carrier [7] . In addition, BRCA1/2 mutations also appear to predispose to a range of other cancer types (prostate, pancreatic, colon cancer etc.) [3] . A relevant proportion of male breast cancer cases are specifically associated with BRCA2 mutations, especially when occurring in familial aggregation of breast/ovarian cancer [8] .
In general, a complete spectrum of genetic alteration (including point mutation, small deletions and insertions, and mutation that impact on RNA splicing) may affect BRCA1/2 genes on their entire sequence. The absence of hot-spot regions therefore requires whole-genes screening approaches. Only in specific ethnic groups (including among others Ashkenazi Jewish) does a significant association with founder mutations allow focused and less expensive screening approaches.
Mutation screening techniques vary in their sensitivity, and methods widely used to detect pathogenic BRCA1/2 genes mutations are usually PCR-based. In particular, techniques such as SSCP and CSGE, miss nearly a third of the mutations that are detected by DNA direct sequencing [9] . Unfortunately genomic rearrangements that alter the integrity of the gene structure are not readily identified by this techniques and a small, but significant increase in mutation detection rate has resulted by use of methods able to identify this type of genetic alterations [10] .
High-risk families are usually selected for BRCA1/2 mutation screening based on proband features (such as primary tumor, age at onset, breast and ovarian cancer association, presence of a male breast cancer and ethnicity) and familial cancer history. Unfortunately, even under stringent selection criteria, the percentage of families without evidence of BRCA1/2 pathogenic alterations ranges between 60% and 80%. In this context, the considerably high costs of BRCA1/2 mutation screening, together with the expanding request for inherited breast/ovarian cancer counseling and genetic testing, prompted the development of tools that might help in the selection of the appropriate candidates for the analysis. These include, among others, BRCApro, IC software, BOADICEA and Myriad Tables, whose efficacy has been validated in several reports [11] [12] [13] [14] [15] .
During the last decade, genetic testing for breast/ovarian cancer susceptibility has been incorporated into the clinical practice. However, several aspects remain to be properly addressed. In particular, although the prevalence and the spectrum of BRCA1/2 mutations in the Italian population have been investigated by several groups, additional efforts may provide further insights in the field. Indeed our recent work expanded the spectrum of BRCA1/2 mutation in Italy by 15% [16] and we found and report here additional undescribed BRCA2 mutations. Furthermore, stratification of our family sample into different profiles allowed us to identify specific aspects relating to mutation frequencies and the efficiency of the different carrier status prediction models.
patients and methods
From March 2002 to May 2005 and according to specific criteria we selected 99 unrelated families affected with breast and/or ovarian cancer, after interview at the Genetic and Oncology Counselling Centre of the Policlinico Umberto I, University 'La Sapienza'. Pre-test counseling was performed by an expert cancer risk counselor and the probands analyzed in this study belonged to different high-risk classes. Selection criteria were as follows: (i) three or more breast cancer cases diagnosed at any age or two first-degree family members affected before 50; (ii) early onset breast cancer (<35 years); (iii) breast and ovarian cancer in the same individual or two breast cancer cases and at least one ovarian cancer case, or one breast cancer case and one ovarian cancer case diagnosed before 50 in first-degree family members; (iv) two or more ovarian cancer cases; and (v) male breast cancer cases were recruited regardless of age and family history.
For each family, we selected a breast and/or ovarian cancer-affected individual as the index case (proband) for BRCA1 and BRCA2 mutation screening. For each proband, the a priori probability of carrying a pathologic BRCA1/2 germline mutation was calculated by either BRCApro (CA Gene) or IC software (version 3.4), or by the Myriad prevalence mutation tables (update spring 2005, http://www.myriadtests.com/provider/mutprev.htm). According to ASCO directions [17, 18] we classified our index cases as 'carrier-positive' when their carrier probability exceeded 10% and 'carrier-negative' when their probability was <10%.
After obtaining an informed consent, genomic DNA was extracted from peripheral blood of all probands using commercial kit (Qiamp Blood Kit, Qiagen, Valencia, CA). The entire coding sequences and each intron/exon boundary of BRCA1 and BRCA2 were screened by protein truncation test (PTT, limited to BRCA1 exon 11) and/or direct sequencing. All truncating and/or novel genetic variants were confirmed by sequencing different samples on both DNA strands. Frequencies of previously unreported BRCA1 and BRCA2 variants were also established on a control population composed of 50 healthy Italian donors. Sequencing was performed using an ABI PRISM DyeDeoxy Terminator Cycle Sequencing Kit and an ABI 3100 Genetic Analyzer (Applied Biosystems, Warrington, UK). Reference sequence for BRCA1 was Genbank, U14680.1 and reference sequence for BRCA2 was Genebank, NM_000059.1. BRCA1/2 genomic rearrangements were searched for by the Multiple Ligation dependent Probe Amplification (MLPA) methodology [19] . MLPA procedure was carried out according to the manufacturer's instructions. Variations in peak height were evaluated comparing each sample with a normal control and by a cumulative comparison.
results and discussion
Over about 3 years, 152 unrelated breast and/or ovarian cancer families underwent cancer genetic counseling in our centre. According to homogeneous selection criteria, we identified 99 families eligible for BRCA1/2 germline mutation analysis through a highly sensitive protocol. The genetic testing, performed on an index case for each family, resulted in the identification of 25 and 52 variants in the BRCA1 and BRCA2 genes, respectively. Most of these were polymorphisms and intronic variants of probably negligible pathogenic significance Annals of Oncology symposium article (Figures 1 and 2) . In contrast, we identified 27 deleterious germline mutations. As depicted in Figures 1 and 2 , they included nonsense, frameshift and splicing site mutations all leading to protein products prematurely truncated. We also identified a missense variant (BRCA1 C61G) for which a pathogenic significance was previously established [20] .
Most of these mutations had already been reported in the Breast Cancer Information Core Database (BIC: http:// research.nhgri.nih.gov/bic/). However, four are novel deleterious mutations (472insA, E33X, IVS6+1G>C, C1630X) on the BRCA2 gene. Two of these (472insA and E33X) have recently been described [16] . They affected exon 3 and are likely to represent very penetrant alleles since both occurred in families characterized by many affected individuals with male and female breast cancer cases, often bilateral or with early onset, and associated with ovarian or endometrial carcinoma. The IVS6+1G>C is a variant that abolishes the canonical GT consensus signal at the exon 6/intron 6 junction. To our knowledge, this specific mutation has never been described previously. However, a very similar mutation (IVS6+1G>A) affecting the same splicing signal was recently described and resulted in the production of different aberrant BRCA2 transcripts missing either exon 6 or exon 5 or both [21] . The IVS6+1G>C mutation is expected to lead at least to exon 6 skipping, thus generating a prematurely truncated protein (stop 168). It occurred in a family (BR136) with four different breast cancer cases on each arm of the genealogic tree. Interestingly both these IVS6+1G mutations are associated with families with no occurrence of ovarian cancer. The BRCA2 C1630X is a previously unreported mutation occurring in a 45-year-old female patient (BR 170) who belonged to a very high-risk family characterized by seven cases of breast cancer and one case of acute linfoblastic leukaemia. Segregation analysis in these families is currently ongoing.
Among the truncating mutation we also found the K3326X in several families. However the role of this mutation in cancer predisposition is still unclear (as discussed in [16] ), and thus we did not considered it among the pathogenic mutations.
A recent work by Marroni et al. [7] reviewed the spectrum of pathogenic BRCA1 and BRCA2 mutations in the Italian population and suggested the presence of at least 50 and 40 deleterious alterations, respectively. Our work largely extended this number [16] and further increased it with the novel mutations reported in this paper. In addition we identified a number of missense variants of ambiguous significance, defined as unclassified variants (UCV, Figures 1 and 2 ). These mutations probably include both insignificant changes and low penetrance alterations with a modifier effect. Both of them 
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Annals of Oncology occur with relatively high frequency and are also found in control individuals [22, 23] . The contribution of these variants to the genetics of breast and ovarian cancer is still a matter of debate and awaits large statistical studies. However, UCV also include mutations only described in high-risk families (and not in control individuals) whose role in cancer susceptibility needs to be demonstrated. The A495T and Q499 are novel BRCA2 variants expected to cause significant modifications in proximity of the FANCG binding domain. We recently showed them to occur in very high-risk families, with no other obvious pathogenic mutation [24] . Their significance will be further studied.
We also used our series to define better the frequency of BRCA1/2 mutations in the Italian population and to verify the efficiency of three different carrier status prediction models.
The prevalence of BRCA1/2 mutations in at-risk Italian families oscillates between 8% and 37% in the different reports present in the literature [25] [26] [27] . Several reasons might explain this broad range, including inconsistency in the different selection criteria and screening methodologies used by the different researchers. We recently reported a mutation frequency of 27.4%, with an equal involvement of BRCA1 and BRCA2 genes [16] . Extending our study up to 99 families left the overall mutation frequency almost unchanged (27.3%, Table 1 ). At variance with other Italian groups [26] , we failed to observe a higher frequency of BRCA2 mutations and we now report a slightly higher proportion of BRCA1 mutations ( Table 1) .
Stratification of our sample into four subgroups allowed a more detailed analysis. Hereditary breast cancer (HBC) families accounted for the large majority of our sample (68%). However we only found 13 pathogenic mutations in this subset, accounting for the lowest mutation frequency (19.4%, Table 1 ). In particular, we detected very few BRCA1 mutations (n = 4) compared to BRCA2 (n = 9). In contrast we detected a high rate of BRCA1 pathogenic mutations in families belonging to the hereditary breast/ovarian cancer (HBOC) and hereditary ovarian cancer (HOC) families (50% and 100%, respectively), with no BRCA2 mutations.
Male breast cancer (MBC) families now represent about 10% of our series. Compared with our previous report we screened more breast cancer patients without familial history of breast cancer, finding no mutations. As a result we have a lower mutation frequency (27.3%) in this group. These data still support the idea of a relevant association between first-degree familial history of breast cancer and BRCA2 deleterious mutations. 
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An interesting topic is the possibility of predicting the BRCA1/2 mutation carrier status by means of appropriate prediction models, in order to reduce the high costs of genetic testing. The BRCApro and the Myriad mutation prevalence tables are among the models that have gained the attention of most people in the field. We have previously tested the performances of these models and compared them to an Italian customized version of the BRCApro software, termed IC software [28] . Our results indicated that all models might represent helpful tools for the selection of BRCA1/2 mutation carriers. Here we extended the analysis to 99 families. Analysis of the receiving operating characteristics (ROC) curves for the three models indicated that none of them strikingly excelled compared with the others (not shown). In line with our previous report, when we looked at the sensitivity we found better performances of the IC software and Myriad Tables  (85% and 89% , respectively) compared with the BRCApro software (67%, Table 5 ). In any case, all methods misclassified mutated probands. Indeed, BRCApro analysis resulted in false-negative indication in 8% of the total sample, while IC software and Myriad tables only lead to 4% and 3% misclassification, respectively (Tables 2-4). Overall performances of the IC software are reappraised by its poor specificity (Table 5) , which would account for a higher number of families screened for BRCA1/2 mutations, compared with the other two models.
An interesting issue raised by our previous work is the relatively low mutation detection rate in pure HBC families In bold: mutated cases with carrier probability <10%. In bold: mutated cases with carrier probability <10%.
symposium article Annals of Oncology [16] . In addition, in this subset the three prediction models proved to be particularly prone to failure (Table 2) with BRCApro performing five failures compared to two and three failures of IC and Myriad tables, respectively. This does not appear as a minor issue since pure HBC families account for the large majority of our sample. These observations led us to hypothesize that perhaps other types of BRCA1/2 mutations or other candidate genes should be searched for in this specific subset [16] . In order to test this hypothesis we selected eight families negative to our conventional screening approach and with BRCApro or IC prediction scores ‡95%. These probands were further studied for BRCA1 and BRCA2 rearrangements by the Multiple Ligation dependent Probe Amplification (MLPA) procedure. Interestingly, although not yet completed, this work already resulted in the identification of a mutated proband, carrying defects in BRCA1 exon 23 and exon 24 MLPA signals, probably indicative of an exon 23/24 deletion. This mutation occurred in a female proband (BR59) who developed a breast cancer at age 28 and belonged to a very high-risk family characterized by four cases of breast cancer in first-degree family members. These preliminary results possibly indicate that similar HBOC and MBC families negative for BRCA1/2 point mutations [10] , and also pure HBC families with high prediction scores obtained by BRCApro and/or IC but negative to conventional screening approaches, are likely to carry large genetic alterations. In bold: mutated cases with carrier probability <10%. 
